Who We Are
STEVE ECKERT (CEO and Board Member)
Over thirty-five years of experience in pharmaceutical industry marketing and sales for large and emerging pharmaceutical companies. Sold Medical Education business to Palo Alto-based HGGC private equity firm for 100X exit on initial investment.
WADE BENTON, Pharm.D. (Chairman of the Board)
Pharmaceutical Executive Scientist with over 20 years in rare disease drug development. Experience developing therapies for PAH, Scleroderma, Cystic Fibrosis, Interstitial Lung Diseases and Pediatrics. Previously Actelion US medical lead for Prostacyclin PAH franchise. Founder and previous CEO, Chairman of Board of Eicos Sciences which received FDA approval for AURLUMYN in 2024.
KEVIN CHRISTAL (Board Member)
Pharmaceutical Executive with over 20 years in drug development and commercialization. Previously Actelion US commercial lead for PAH franchise. Launched multiple therapies including blockbuster UPTRAVI (selexipag) in PAH. Founder Eicos Sciences which received FDA approval for AURLUMYN in 2024.
ANSGAR CONRAD, Ph.D. (Board Member)
Pharmaceutical Executive Scientist with over 20 years in Medical Affairs and Advocacy. Extensive US launch experience in PAH. Previously medical lead for Actelion US PAH franchise. Launched blockbuster Opsumit in PAH. Medical Affairs lead at Relypsa & Vifor. Currently VP, Med Affairs at Prothena Biosciences.
